Merit Medical (MMSI) Q1 2026 Earnings Transcript

Merit Medical posted a strong Q1 with revenue of $381.9 million (+7% GAAP, +5% constant currency), non-GAAP EPS of $0.94 (+9%), and free cash flow of $25 million (+26%), all above the high end of guidance. Management raised FY2026 revenue expectations to 6.3%-7.8% growth and reaffirmed EPS of $4.10-$4.15, despite a $4.6 million tariff hit in the quarter and a projected $15 million full-year tariff impact. The company also closed the $140 million Viewpoint Medical acquisition and launched the Resilience esophageal stent, supporting longer-term growth in oncology and endoscopy.

Analysis

MMSI is quietly demonstrating the kind of earnings quality that usually supports multiple expansion: organic growth is re-accelerating, margin leverage is still showing through despite tariff drag, and cash conversion remains strong. The more important second-order signal is that management is using the current environment to re-segment the business around higher-confidence platforms, which should reduce the market’s tendency to value it as a generic med-tech roll-up and instead reward it more like a platform aggregator with distinct growth engines.

The Viewpoint deal matters less for the near-term revenue than for what it says about distribution economics. OneMark appears to widen the total addressable biopsy-localization market rather than steal share from SCOUT, which means the real upside is account expansion and physician preference capture, not just cross-selling into the same installed base. If execution is real, the mix shift should also improve gross margin durability because the acquired asset carries materially better unit economics than the company average, giving MMSI a path to offset tariff pressure without needing broad-based price increases.

The market is likely underappreciating how much of the current near-term noise is timing-related rather than structural: OEM destocking, Middle East shipping delays, and tariff uncertainty all compress visible growth, but they also create setup for sequential improvement over the next two quarters. The main bear case is that investors discount the guidance because it embeds multiple moving parts—tariffs, acquisition dilution, and product ramp assumptions—yet the balance sheet still leaves room for continued M&A and share repurchases later if management chooses to pivot capital allocation. In other words, the stock is being asked to prove several optionality points at once, which can cap the multiple in the short run even as fundamentals improve.

Key Decisions for Investors

• Go long MMSI on a 3-6 month horizon; use weakness from tariff headlines or OEM volatility as entry points. Risk/reward favors the upside if Q2 confirms mid-single-digit OEM recovery and Viewpoint begins to show early adoption.
• Consider a MMSI / MDT pair trade: long MMSI, short MDT on a relative-value basis. MMSI has clearer self-help catalysts, better margin trajectory, and more visible acquisition-driven growth optionality over the next 12 months.
• Buy MMSI call spreads or a stock replacement strategy into the next earnings cycle if implied volatility remains moderate. The setup is asymmetrical if management reiterates the 2026 guide and commentary on tariffs improves at the next update.
• Avoid chasing after a sharp post-earnings move; prefer staged accumulation over 2-4 weeks. The key technical risk is that the market waits for evidence that OneMark ramps without cannibalizing SCOUT before awarding a higher multiple.
• For more defensive capital, pair a long MMSI with a short basket of weaker med-tech OEM-exposed names. The idea is that MMSI’s OEM lumpiness is improving while many peers still face demand and channel-inventory overhangs.